0001493152-26-020510
SEC filingFiscal 2025 was a challenging year with operating losses and cash burn, offset by insider-led debt conversions and equity raises that stabilized the balance sheet.
OneMedNet's revenue increased during fiscal 2025, driven by new enterprise customer agreements and expanded utilization of its iRWD (regulatory-grade real-world data) platform. The company secured several multi-year contracts with pharmaceutical and biotech firms, reflecting growing demand for de-identified medical imaging data in clinical research. While absolute revenue remains modest relative to peers, the shift toward higher-value data licensing agreements improved revenue quality and visibility. Management noted that the sales pipeline is strengthening, with particular traction in oncology and neurology therapeutic areas.
Despite revenue growth, the company reported significant operating losses as it continued to invest heavily in sales, marketing, and product development. Gross margin improved during the year, benefiting from a mix shift toward higher-margin data licensing revenue versus lower-margin professional services. However, operating expenses grew faster than revenue, driven by headcount additions in the commercial team and increased spending on AI and machine learning capabilities to enhance the iRWD platform. The company remains in an investment phase, with management prioritizing top-line growth and platform expansion over near-term profitability.
Cash burn from operations persisted, funded primarily through related-party debt conversions and equity placements. The company did not raise external debt during the period. The conversion of related-party debt into equity strengthened the balance sheet by reducing leverage, though the exact amount of debt converted was not disclosed in the financial statements. Management continues to rely on insider support for financing, which mitigates near-term liquidity risk but highlights dependence on related parties.
Management's outlook emphasizes continued investment in the iRWD platform, AI capabilities, and commercial expansion. The company did not provide quantitative guidance but signaled that it expects revenue to grow as it scales enterprise contracts and expands its data network. Key risks include the ability to achieve profitability, reliance on related-party financing, and competition from larger data aggregators. The recent appointments of experienced directors and the establishment of a Commercial Committee suggest a focus on accelerating revenue growth. Investors should monitor cash burn, customer concentration, and the pace of new contract wins as leading indicators of progress.